Best of heart failure

36 References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance 1. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam Study. Eur Heart J. 2004;25(18):1614 – 9. 2. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole- Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20(6):421 – 8. 3. FonarowGC, Heywood JT, Heidenreich PA, LopatinM, Yancy CW, Committee ASA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153(6):1021 – 8. 4. Tsuyuki RT, McKelvie RS, Arnold JM, Avezum A Jr, Barretto AC, Carvalho AC, et al. Acute precipitants of congestive heart failure exacerbations. Arch InternMed. 2001;161(19):2337 – 42. 5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA focused up- date on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the Ameri- can College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68(13):1476 – 88. 6. Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Associa- tion of the European Society of Cardiology. Eur J Heart Fail. 2007;9(6 – 7):684 – 94. 7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810 – 52. 8. • Kirklin JK, Naftel DC, Stevenson LW, Kormos RL, Pagani FD, Miller MA, et al. INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant. 2008;27(10):1065 – 72 The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profiles provide important prognostic information for patients with advanced heart fail- ure (HF) receiving mechanical support. Although it has not been validated for patients with advanced heart failure under- going revascularization, it remains an important tool to classify and prognosticate these patients prior to revascularization. 9. Perera D, Clayton T, Petrie MC, Greenwood JP, O'Kane PD, Evans R, et al. Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy. JACC Heart Fail. 2018;6(6):517 – 26. 10. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart fail- ure: a position statement of the Heart Failure Associa- tion of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505 – 35. 11. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891 – 975. 12. •• Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607 – 16 STICHES was an extended follow-up of patients from the STICH trial, which found no differences in mortality rates between the groups at 56 months. However, at 10 years, CABG plus medical therapy significantly reduced mortality rates in patients with ischemic cardiomyopathy when compared to medical therapy alone. 13. •• Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in pa- tients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1511 – 20 STICHES was an extended follow-up of patients from the STICH trial, which found no differences in mortality rates between the groups at 56 months. However, at 10 years, CABG plus medical therapy significantly reduced mortality rates in patients with ischemic cardiomyopathy when compared to medical therapy alone. 14. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Hannan EL. Revascularization in patients with multivessel cor- onary artery disease and severe left ventricular systolic dysfunction: everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation. 2016;133(22):2132 – 40. 15. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries Curr Treat Options Cardio Med (2019) 21: 4 Page 11 of 12 4